By law, virtually all new policies proposed in the European Union (EU) must undergo an "impact assessment" (IA): a review of the potential economic, social, and environmental consequences. The outcome of such review is heavily influenced by the type of impact assessment tool used. IA tools focusing on economic impacts, for example, tend to favor regulation increasing business profits, even if such policies undermine general public health. Independent experts have suggested that the EU's current IA tool, which focuses heavily on economic impacts, does not adequately take policies' health impacts into account.

Now, this new PLoS Medicine article provides evidence that BAT, working with companies from other sectors (including chemical, oil and food companies), played a key role in shaping the EU's current business-oriented IA system.

Dr Katherine Smith and colleagues (University of Bath; University of Edinburgh) analyzed over 700 internal BAT documents containing information on BAT's attempts to influence European regulatory reform, and interviewed relevant European policymakers and lobbyists. They found that BAT created a policy network comprised of representatives from a number of large corporations involved in marketing products that are damaging to public health and the environment, to promote a lobbying campaign to alter EU policymaking rules.

The campaign resulted in specific changes to the EU Treaty calling for policymakers to reduce the regulatory burden on businesses, ultimately fostering the current system of business-oriented IA, which may well stall or even prevent future EU public health regulations, say the authors. Moreover, the authors report that EU officials were often unaware of the magnitude of BAT's influence -- presumably due to the latter's creation of a policy network and the campaign's use of third parties, such as think tanks and consultancy companies.

The authors suggest that BAT and its corporate allies laid the groundwork for a policy evaluation system in the EU which emphasizes corporate interests over citizens' health. Increased transparency, awareness of corporations' policy influence and greater understanding of the IA system are thus needed to ensure that EU policies required to protect public health continue to emerge.

Note: If no author is given, the source is cited instead.

• Health Policy
• Workplace Health
• Today's Healthcare

• Public Health
• Educational Policy
• Political Science

• Environmental impact assessment
• Pharmaceutical company
• Genetically modified food
• Food and Drug Administration
• Clinical trial
• Tobacco smoking